Skip to main content
. 2017 Sep 7;23(33):6128–6136. doi: 10.3748/wjg.v23.i33.6128

Figure 3.

Figure 3

Time to discontinuation of first-line treatment. By 588 d of treatment (1.61 yr), half of SSA initiators had discontinued treatment, compared to 182 d (0.498 yr) for half of CC users and 171 d (0.47 yr) for half of TT users to discontinue treatment. SSA: Somatostatin analogues; CC: Cytotoxic chemotherapy; TT: Targeted therapy.